StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Veracyte price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Veracyte's price to sales ratio was 3.6× on Nov 11, 2026, against 7.6× a year earlier. Over the last 5 years it ranged from 3.6× to 15.7×, with a median of 5.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.6×−3.1
2025Dec 31, 20256.7×−0.5
2024Dec 31, 20247.2×+1.4
2023Dec 29, 20235.9×−0.2
2022Dec 30, 20226.0×−9.7
2021Dec 31, 202115.7×−9.4
2020Dec 31, 202025.1×+13.4
2019Dec 31, 201911.7×+5.8
2018Dec 31, 20185.9×+2.8
2017Dec 29, 20173.1×−0.4
2016Dec 30, 20163.6×−0.6
2015Dec 31, 20154.2×−2.4
2014Dec 31, 20146.6×+5.9
2013Dec 31, 20130.7×–

More Veracyte figures

See a number that looks wrong?